["Sofosbuvir (SOF) was the first directly acting antiviral (DAA) made available for chronic hepatitis C (CHC) in India. We describe our 'real life' experience of using SOF with ribavirin (RBV) with or without pegylated interferon (PegIFN) in predominant genotype 3 patients with CHC.", '158 patients [Males 99 (62.6%), mean age 40.3\u2009±\u200912.8\u2009years) with CHC treated with dual therapy (SOF\u2009+\u2009RBV) for 24\u2009weeks or triple therapy (PegIFN\u2009+\u2009SOF\u2009+\u2009RBV) for 12\u2009weeks were included prospectively. Patients with co-infection, decompensated liver disease and post organ transplantation were excluded. Data was analysed for the preference of treatment regimen, end of treatment response (ETR), sustained virological response at 12\u2009weeks (SVR12) and side effects.', 'Genotype 3 was the predominant genotype [105 (66.4%)] followed by genotype 1 [40 (25.3%)] and genotype 4 [13(8.2%)]. 48 (30.37%) patients had cirrhosis (LSM ≥13kPa) and 30(19%) were treatment experienced (TE) with PegIFN\u2009+\u2009RBV. 103 (65.18%) patients received dual therapy and 55(34.81%) received triple therapy. Resentment to receive injections, inaccessibility to a facility, fear of injection or its side effects and financial constraints were the reasons to refuse triple therapy. All patients in triple therapy group and all but 2 patients (98%) in the dual therapy group attained ETR. All those who achieved ETR, achieved SVR12 in both groups. But for anemia in 3 patients (2 in triple, one in dual therapy) there were no major side effects.'] Is dual treatment with sofosbuvir plus ribavirin as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C?